Department of Medicine, James A. Haley VA Medical Center, University of South Florida for Health Sciences, Tampa, FL, USA.
Anticancer Res. 2012 Mar;32(3):721-5.
Four cardiac peptide hormones, namely vessel dilator, long-acting natriuretic peptide (LANP), kaliuretic peptide, and atrial natriuretic peptide (ANP) have anticancer effects.
The effects of these four cardiac hormones on human c-Jun-N-terminal kinase 2 (JNK2) were examined in human small cell lung cancer and human prostate cancer cells.
Vessel dilator, LANP, kaliuretic peptide and ANP maximally reduced expression of JNK2 by 89%, 56%, 45%, and 28%, respectively (each at p<0.0001) in human small cell lung cancer cells. In human prostate adenocarcinoma cells, JNK2 was maximally decreased 76%, 56%, 45%, (each at p<0.0001), and 28% (p<0.01) secondary to vessel dilator, LANP, kaliuretic peptide and ANP, respectively.
These results indicate that four cardiac hormones are significant inhibitors (by up to 89%) of JNK2 in human small cell lung cancer cells and up to 76% in human prostate adenocarcinoma cells as part of their anticancer mechanism(s) of action.
四种心脏肽激素，即血管舒张素、长效利钠肽（LANP）、利钾肽和心房利钠肽（ANP）具有抗癌作用。
研究了这四种心脏激素对人小细胞肺癌和人前列腺癌细胞中 c-Jun-N-末端激酶 2（JNK2）的影响。
血管舒张素、LANP、利钾肽和 ANP 分别使小细胞肺癌细胞中 JNK2 的表达最大减少 89%、56%、45%和 28%（p<0.0001，每组）。在人前列腺腺癌细胞中，JNK2 最大减少 76%、56%、45%（p<0.0001，每组）和 28%（p<0.01），分别继发于血管舒张素、LANP、利钾肽和 ANP。
这些结果表明，四种心脏激素是人小细胞肺癌细胞中 JNK2 的显著抑制剂（最大可达 89%），在人前列腺腺癌细胞中高达 76%，这是它们抗癌作用机制的一部分。
